Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 2a multicenter, randomized study to evaluate targeted therapies for adults with moderate to severe Crohn’s Disease. The study aims to assess the effectiveness and safety of specific treatments, which is crucial given the chronic nature of Crohn’s Disease and the varying response to existing treatments.
The study tests three drugs: Risankizumab, ABBV-382, and Lutikizumab. These are administered either as monotherapies or in combination, using subcutaneous injections and intravenous infusions, to reduce inflammation in the digestive tract.
The study is interventional, with a randomized allocation and a sequential intervention model, focusing on treatment as the primary purpose. There is no masking involved, meaning both researchers and participants know which treatments are being administered.
The study began on September 4, 2024, with primary completion expected in 2025. The latest update was submitted on July 15, 2025, indicating ongoing recruitment and progress.
This study could significantly impact AbbVie’s market position by potentially expanding its portfolio of treatments for Crohn’s Disease, influencing investor sentiment positively. Competitors in the gastrointestinal treatment space will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.